Nasdaq · Biotech stocks database
TGTX (TG Therapeutics Inc.) stock: $56.87, $8.71B market cap, $552.2M cash, $8.90B EV, $9.62B fully diluted market cap. Next expected readout: Oct-26. Lead program: Ublituximab (Relapsing Multiple Sclerosis), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $552.2M |
|---|---|
| Debt | $745.4M |
| Net cash | -$193.2M |
| Enterprise value | $8,898.2M |
| Basic shares | 153.1M shares |
| Fully diluted shares | 169.2M shares |
| Fully diluted market cap | $9,619.8M |
| Cash per share | $3.61 |
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Loading TGTX daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Dec 12, 2026 - Jan 23, 2027 | Ublituximab | Phase 3 | Relapsing Multiple Sclerosis | — |
| Jan 12 - Feb 23 | Azercabtagene zapreleucel (azer-cel) | Phase 1 | B-cell Mediated Autoimmune Disorders | — |
| Mar 4 - Apr 15 | Ublituximab | Phase 3 | Relapsing Multiple Sclerosis | — |
| Sep 11 - Oct 23 | Ublituximab | Phase 2 | Multiple Sclerosis | — |
| Aug 12 - Sep 23 | Ublituximab | Phase 2 | Myasthenia Gravis | — |
| Jan 23 - Mar 6 | Ublituximab | Phase 2 | Schizophrenia | — |
| Feb 12 - Mar 26 | Ublituximab | Phase 2/3 | Relapsing Multiple Sclerosis | — |
| Jul 12 - Aug 23 | Ublituximab | Phase 3 | Relapsing Multiple Sclerosis (RMS) | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.